Mitogen-activated protein kinase 14 (p38 MAPK alpha) (MAPK14)

Mitogen-activated protein kinase 14 (MAPK14), widely known as p38 MAPK alpha, is a critical serine/threonine kinase that mediates cellular responses to external stressors such as UV radiation, heat shock, and osmotic stress, as well as pro-inflammatory cytokines (UniProt: Q16539). It is the most well-characterized isoform of the p38 family and is ubiquitously expressed in most tissues, playing a central role in the regulation of the immune response (PubMed: 25659706). Upon activation by upstream kinases like MKK3 or MKK6, p38 alpha phosphorylates a wide array of substrates, including transcription factors and other kinases, which ultimately drive the expression of genes involved in inflammation, cell cycle control, and apoptosis (PubMed: 10891884). In the context of disease, overactivation of p38 alpha is linked to chronic inflammatory conditions like rheumatoid arthritis and COPD, as well as certain cancers and neurodegenerative disorders (PubMed: 29435140). Consequently, numerous small-molecule inhibitors have been developed to target p38 alpha, though many have faced challenges in clinical trials due to off-target effects, hepatotoxicity, or lack of sustained efficacy (PubMed: 26101222). Current research continues to explore its potential in niche indications, such as Alzheimer's disease and facioscapulohumeral muscular dystrophy, through more selective or allosteric inhibition strategies (PubMed: 30254044).

Other names

p38-alphaSAPK2ACSBPCSBP1CSBP2CSPB1MXI2PRKM14PRKM15RK

Inhibition of p38 MAPK alpha typically involves ATP-competitive binding or allosteric modulation (Type II inhibitors) that stabilizes the inactive DFG-out conformation of the kinase, thereby preventing the phosphorylation of downstream targets such as MAPKAPK2 and the subsequent production of pro-inflammatory cytokines like TNF-alpha and IL-1 beta (PubMed: 10891884, PubMed: 26101222).